A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Allergan419 enrolled

Overview

A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.

Study Type

OBSERVATIONAL

Enrollment

419

Conditions

Glaucoma, Open-Angle Ocular Hypertension

Interventions

bimatoprost 0.01% ophthalmic solutionDRUG

Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of POAG or OHT * Prescribed Lumigan® 0.01% Exclusion Criteria: * None

Locations (1)

Unnamed facility

Vienna, Austria

Outcomes

Primary Outcomes

Intraocular Pressure (IOP) at Baseline

IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eyes at Baseline.

Time frame: Baseline

IOP at Week 14

IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eyes at Week 14.

Time frame: Week 14

Secondary Outcomes

Physician Evaluation of IOP Lowering in the Study Eye(s)

IOP is a measurement of the fluid pressure inside the eye. Physicians evaluated IOP compared to the target IOP for each patient's study eye(s). The numbers of eyes in each category are presented.

Time frame: Week 14

Patient Assessment of Tolerability on a 4-Point Scale

Patient assessment of tolerability was assessed using a 4-point scale (very good, good, moderate, and poor). The numbers of patients in each category are presented.

Time frame: Week 14

Physician Assessment of Tolerability on a 4-Point Scale

Physician assessment of tolerability was assessed using a 4-point scale (very good, good, moderate, and poor). The numbers of patients in each category are presented.

Time frame: Week 14

Percentage of Patients Who Discontinue Lumigan® 0.01% Prior to 14 Weeks of Treatment

Patients who discontinued Lumigan® 0.01% prior to 14 weeks was assessed as Yes or No.

Time frame: 14 Weeks

Percentage of Patients Who Continue Lumigan® 0.01% Treatment

Patients who will continue Lumigan® 0.01% after 14 weeks of treatment was assessed as Yes or No.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.